Prostate Cancer Reports

Volume 7 Number 1
January 2019


Home > Prostate Cancer Reports > Volume 7, Year 2019 > Number 1, January


CONTENTS


DIAGNOSIS
EPIDEMIOLOGY, RISK FACTORS, PREVENTION
FOLLOW-UP, QUALITY OF LIFE
PROGNOSIS
TREATMENT



DIAGNOSIS

.

Müller J, Ferraro DA, Muehlematter UJ, Garcia Schüler HI, Kedzia S, Eberli D, Guckenberger M, Kroeze SGC, Sulser T, Schmid DM, Omlin A, Müller A, Zilli T, John H, Kranzbuehler H, Kaufmann PA, von Schulthess GK, Burger IA.
Clinical impact of 68Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction.
Eur J Nucl Med Mol Imaging. 2018 Nov 28. doi: 10.1007/s00259-018-4203-0. [Epub ahead of print]
Source | FTL | Similar articles



.

Osses DF, Remmers S, Schröder FH, van der Kwast T, Roobol MJ.
Results of Prostate Cancer Screening in a Unique Cohort at 19yr of Follow-up.
Eur Urol. 2018 Nov 9. pii: S0302-2838(18)30851-0. doi: 10.1016/j.eururo.2018.10.053. [Epub ahead of print]
Source | FTL | Similar articles



.

Rouvière O, Puech P, Renard-Penna R, Claudon M, Roy C, Mège-Lechevallier F, Decaussin-Petrucci M, Dubreuil-Chambardel M, Magaud L, Remontet L, Ruffion A, Colombel M, Crouzet S, Schott AM, Lemaitre L, Rabilloud M, Grenier N; MRI-FIRST Investigators.
Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study.
Lancet Oncol. 2018 Nov 20. pii: S1470-2045(18)30569-2. doi: 10.1016/S1470-2045(18)30569-2. [Epub ahead of print]
Source | FTL | Similar articles



EPIDEMIOLOGY, RISK FACTORS, PREVENTION

.

Hurwitz LM, Joshu CE, Barber JR, Prizment AE, Vitolins MZ, Jones MR, Folsom AR, Han M, Platz EA.
Aspirin and Non-Aspirin NSAID Use and Prostate Cancer Incidence, Mortality, and Case-Fatality in the Atherosclerosis Risk in Communities Study.
Cancer Epidemiol Biomarkers Prev. 2018 Nov 28. pii: cebp.0965.2018. doi: 10.1158/1055-9965.EPI-18-0965. [Epub ahead of print]
Source | FTL | Similar articles



.

Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, Gibson H, Gordon D, Copeland T, D'Agostino D, Friedenberg G, Ridge C, Bubes V, Giovannucci EL, Willett WC, Buring JE; VITAL Research Group.
Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease.
N Engl J Med. 2018 Nov 10. doi: 10.1056/NEJMoa1809944. [Epub ahead of print]
Source | FTL | Similar articles



.

Shang Z, Wang X, Yan H, Cui B, Wang Q, Wu J, Cui X, Li J, Ou T, Yang K.
Intake of Non-steroidal Anti-inflammatory Drugs and the Risk of Prostate Cancer: A Meta-Analysis.
Front Oncol. 2018 Oct 23;8:437. doi: 10.3389/fonc.2018.00437. eCollection 2018.
Source | FTL | Similar articles



FOLLOW-UP, QUALITY OF LIFE

.

Moschini M, Zaffuto E, Karakiewicz PI, Andrea DD, Foerster B, Abufaraj M, Soria F, Mattei A, Montorsi F, Briganti A, Shariat SF.
External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis.
Eur Urol. 2018 Oct 4. pii: S0302-2838(18)30722-X. doi: 10.1016/j.eururo.2018.09.034. [Epub ahead of print]
Source | FTL | Similar articles



.

Wallerstedt A, Strom P, Gronberg H, Nordstrom T, Eklund M.
Risk of Prostate Cancer in Men Treated With 5α-Reductase Inhibitors-A Large Population-Based Prospective Study.
J Natl Cancer Inst. 2018 Nov 1;110(11):1216-1221. doi: 10.1093/jnci/djy036. Epub 2018 Mar 14.
Source | FTL | Similar articles



.

Wu Y, Qu X, Wang Y, Xia J, Gu Y, Qian Q, Hong Y.
Effect of phosphodiesterase type 5 inhibitors on prostate cancer risk and biochemical recurrence after prostate cancer treatment: A systematic review and meta-analysis.
Andrologia. 2018 Nov 16:e13198. doi: 10.1111/and.13198. [Epub ahead of print]
Source | FTL | Similar articles



PROGNOSIS

.

Aas K, Fosså SD, Kvåle R, Møller B, Myklebust TÅ, Vlatkovic L, Müller S, Berge V.
Is time from diagnosis to radical prostatectomy associated with oncological outcomes?
World J Urol. 2018 Nov 27. doi: 10.1007/s00345-018-2570-6. [Epub ahead of print]
Source | FTL | Similar articles



.

Awasthi S, Gerke T, Park JY, Asamoah FA, Williams VL, Fink AK, Balkrishnan R, Lee DI, Malkowicz SB, Lal P, Dhillon J, Pow-Sang JM, Rebbeck TR, Yamoah K.
Optimizing Time-to-Treatment to achieve durable biochemical disease control after surgery in prostate cancer - A multi-institutional cohort study.
Cancer Epidemiol Biomarkers Prev. 2018 Nov 9. pii: cebp.0812.2018. doi: 10.1158/1055-9965.EPI-18-0812. [Epub ahead of print]
Source | FTL | Similar articles



.

Ferro M, Musi G, Serino A, Cozzi G, Mistretta FA, Costa B, Bianchi R, Cordima G, Luzzago S, Di Trapani E, Tagliabue E, Vartolomei MD, Terracciano D, Cassatella MC, Salvatici M, Conti A, Sandri MT, Cioffi A, Turetti M, Catellani M, Bottero D, Matei DV, Mirone V, de Cobelli O.
Neutrophil, Platelets, and Eosinophil to Lymphocyte Ratios Predict Gleason Score Upgrading in Low-Risk Prostate Cancer Patients.
Urol Int. 2018 Nov 8:1-8. doi: 10.1159/000494259. [Epub ahead of print]
Source | FTL | Similar articles



.

Kim DK, Koo KC, Lee KS, Hah YS, Rha KH, Hong SJ, Chung BH.
Time to Disease Recurrence Is a Predictor of Metastasis and Mortality in Patients with High-risk Prostate Cancer Who Achieved Undetectable Prostate-specific Antigen Following Robot-assisted Radical Prostatectomy.
J Korean Med Sci. 2018 Oct 16;33(45):e285. doi: 10.3346/jkms.2018.33.e285. eCollection 2018 Nov 5.
Source | FTL | Similar articles



.

Turan T, Güçlüer B, Efiloğlu Ö, Şendoğan F, Atış RG, Çaşkurlu T, Yıldırım A.
The factors predicting upgrading of prostate cancer by using International Society for Urological Pathology (ISUP) 2014 Gleason grading system.
Turk J Urol. 2018 Aug 17. doi: 10.5152/tud.2018.57946. [Epub ahead of print]
Source | FTL | Similar articles



.

Xu B, Luo C, Zhang Q, Jin J.
Preoperative characteristics of the P.R.O.S.T.A.T.E. scores: a novel predictive tool for the risk of positive surgical margin after radical prostatectomy.
J Cancer Res Clin Oncol. 2017 Apr;143(4):687-692. doi: 10.1007/s00432-016-2313-2. Epub 2016 Dec 5.
Source | FTL | Similar articles



.

Zhang ZN, Luo C, Xu B, Song HF, Ma BL, Zhang Q.
Preoperative PROSTATE scoring system: a potential predictive tool for the risk of biochemical recurrence after radical prostatectomy.
Cancer Manag Res. 2018 Oct 16;10:4671-4677. doi: 10.2147/CMAR.S175869. eCollection 2018.
Source | FTL | Similar articles



TREATMENT

.

Berg S, Cole AP, Krimphove MJ, Nabi J, Marchese M, Lipsitz SR, Noldus J, Choueiri TK, Kibel AS, Trinh QD.
Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer.
Eur Urol. 2018 Nov 9. pii: S0302-2838(18)30820-0. doi: 10.1016/j.eururo.2018.10.032. [Epub ahead of print]
Source | FTL | Similar articles



.

Bottke D, Bartkowiak D, Siegmann A, Thamm R, Böhmer D, Budach V, Wiegel T.
Effect of early salvage radiotherapy at PSA < 0.5 ng/ml and impact of post-SRT PSA nadir in post-prostatectomy recurrent prostate cancer.
Prostate Cancer Prostatic Dis. 2018 Nov 28. doi: 10.1038/s41391-018-0112-3. [Epub ahead of print]
Source | FTL | Similar articles



.

Carter HB, Helfand B, Mamawala M, Wu Y, Landis P, Yu H, Wiley K, Na R, Shi Z, Petkewicz J, Shah S, Fantus RJ, Novakovic K, Brendler CB, Zheng SL, Isaacs WB, Xu J.
Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer.
Eur Urol. 2018 Oct 8. pii: S0302-2838(18)30684-5. doi: 10.1016/j.eururo.2018.09.021. [Epub ahead of print]
Source | FTL | Similar articles



.

Dhondt B, Buelens S, Van Besien J, Beysens M, De Bleser E, Ost P, Lumen N.
Abiraterone and spironolactone in prostate cancer: a combination to avoid.
Acta Clin Belg. 2018 Nov 26:1-6. doi: 10.1080/17843286.2018.1543827. [Epub ahead of print]
Source | FTL | Similar articles



.

Ghiasy S, Abedi AR, Moradi A, Hosseini SY, Karkan MF, Sadri G, Davari M.
Is active surveillance an appropriate approach to manage prostate cancer patients with Gleason Score 3+3 who met the criteria for active surveillance?
Turk J Urol. 2018 Nov 19:1-4. doi: 10.5152/tud.2018.72920. [Epub ahead of print]
Source | FTL | Similar articles



.

Heck MM, Tauber R, Schwaiger S, Retz M, D'Alessandria C, Maurer T, Gafita A, Wester HJ, Gschwend JE, Weber WA, Schwaiger M, Knorr K, Eiber M.
Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer.
Eur Urol. 2018 Nov 22. pii: S0302-2838(18)30873-X. doi: 10.1016/j.eururo.2018.11.016. [Epub ahead of print]
Source | FTL | Similar articles



.

Hu Z, Wang J, Sun D, Cui L, Ran W.
How Many Cores Does Systematic Prostate Biopsy Need?: A Large-Sample Retrospective Analysis.
J Ultrasound Med. 2018 Oct 31. doi: 10.1002/jum.14834. [Epub ahead of print]
Source | FTL | Similar articles



.

Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, Ivashchenko P, Demirhan E, Modelska K, Phung, Krivoshik A, Sternberg CN.
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.
N Engl J Med. 2018 Jun 28;378(26):2465-2474. doi: 10.1056/NEJMoa1800536.
Source | FTL | Similar articles



.

Jereczek-Fossa BA, Rojas DP, Zerini D, Fodor C, Viola A, Fanetti G, Volpe S, Luraschi R, Bazani A, Rondi E, Cattani F, Vavassori A, Garibaldi C, Alessi S, Pricolo P, Petralia G, Cozzi G, De Cobelli O, Musi G, Orecchia R, Marvaso G, Ciardo D.
Reirradiation for isolated local recurrence of prostate cancer: Mono-institutional series of 64 patients treated with salvage stereotactic body radiotherapy (SBRT).
Br J Radiol. 2018 Nov 9:20180494. doi: 10.1259/bjr.20180494. [Epub ahead of print]
Source | FTL | Similar articles



.

Park Y, Park HJ, Jang WI, Jeong BK, Kim HJ, Chang AR.
Long-term results and PSA kinetics after robotic SBRT for prostate cancer: multicenter retrospective study in Korea (Korean radiation oncology group study 15-01).
Radiat Oncol. 2018 Nov 23;13(1):230. doi: 10.1186/s13014-018-1182-z.
Source | FTL | Similar articles



bottom